Cytokinetics Inc. (Nasdaq: CYTK) reported disappointing results from a Phase 3 clinical trial of tirasemtiv to treat patients with amyotrophic lateral sclerosis. Shares of the biopharmaceutical plunged $2.85 to close at $8.25.